Skip to main content

Tina K. Thethi, MD, MPH

Tina K. Thethi, MD, MPH

Associate Investigator and Endocrinologist

Translational Research

Dr. Thethi

Overview

Tina Kaur Thethi MD, MPH is an Associate Investigator at the AdventHealth Translational Research Institute and Endocrinologist at the AdventHealth Diabetes Institute in Orlando, FL. Dr. Thethi got her medical degree from N.K.P Salve Institute of Medical Sciences and Research Center in India. She is board-certified in Internal Medicine and Endocrinology, Diabetes and Metabolism. She did her endocrine fellowship at Tulane University and her Master’s in Public Health from Tulane School of Public Health and Tropical Medicine, in New Orleans, LA. Dr. Thethi has presented at national and regional meetings and is the recipient of the Janet McArthur Award for Excellence in Clinical Research. She is an ad hoc reviewer for several journals. Dr. Thethi’ s research interests center around obesity, type 2 diabetes and it’s complications with a focus on diabetic kidney disease. To better understand the pathogenesis of diabetic kidney disease and find biomarkers that identify diabetic kidney disease earlier is a key goal of Dr. Thethi’ s research career. Other areas of interest include studying gender and racial differences in obesity, endothelial dysfunction, and cardiovascular disease in type 2 diabetes mellitus. She continues to increase her experience in COVID-19 related trials.

Articles

Cardiovascular Outcome Trials with Glucose-Lowering Drugs

CURRENT CARDIOLOGY REPORTS

2021

Sex differences in soluble prorenin receptor in patients with type 2 diabetes

BIOLOGY OF SEX DIFFERENCES

2021

Cardiovascular Outcomes Trials of Incretin-Based Therapies.

Diabetes spectrum : a publication of the American Diabetes Association

2021

Racial and sex differences in the polymorphisms of the endocannabinoid receptor genes in obesity

JOURNAL OF DIABETES AND ITS COMPLICATIONS

2020

Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme

DIABETES OBESITY & METABOLISM

2020

Weight Loss in Underserved Patients - A Cluster-Randomized Trial

NEW ENGLAND JOURNAL OF MEDICINE

2020

Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus

BMJ OPEN

2019

Challenging the conventional wisdom on diabetic nephropathy: Is microalbuminuria the earliest event?

JOURNAL OF DIABETES AND ITS COMPLICATIONS

2019

Promoting Successful Weight Loss in Primary Care in Louisiana (PROPEL): Rationale, design and baseline characteristics

CONTEMPORARY CLINICAL TRIALS

2018

Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly

JOURNAL OF INVESTIGATIVE MEDICINE

2018

Education & Training

Education

N.K.P. Salve Institute Of Medical Sciences

Residency

St Elizabeth Health Center

Fellowship

Tulane University

Specialty

Endocrinology, Diabetes And Metabolism

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT05047263

FIND-CKD: A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease.

Icon for trial | 21177 FIND-CKD: A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diab

Study Purpose: To determine the safety and efficacy of Finerenone along with standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease. To be enrolled in this study, you must m ...

NCT04419779

REVITALIZE-1: A Prospective randomized, double-blind, sham-controlled, multi-center pivotal study to evaluate the efficacy and safety of Duodenal Mucosal Resurfacing (DMR) using the Revita system in subjects with type 2 diabetes on insulin therapy.

Icon for trial | C-00044 REVITALIZE-1: A Prospective randomized, double-blind, sham-controlled, multi-center pivotal study to evaluate the efficacy and safety of Duodenal Mucosal Resurfacing (DMR) using the Revita system in subjects with type 2 diabetes on insulin therapy

This study is currently enrolling.

Study Purpose: The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita System compared to a sham. To be enrolled in this study, you must meet certain requirements. You m ...

NCT05901831

FINE-ONE: A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of Finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease and type 1 diabetes

Icon for trial | 22267 FINE-ONE: A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of Finerenone versus placebo, in addition to standard of care, in participants with chronic ki

This study is currently enrolling.

Study Purpose: The aim of the study is to demonstrate efficacy of Finerenone when compared to placebo, in addition to standard of care, in delaying the progression of chronic kidney disease (CKD) in participants with CKD and T1 ...